The purpose of this study was to evaluate differences in vaginal immune cell populations, vaginal tissue gene expression, antimicrobial activity of the cervicovaginal (CV) lavage (CVL), vaginal flora, and p24 antigen production from CV tissues after ex vivo human immunodeficiency virus (HIV) infection between follicular (FOL) and luteal (LUT) phases of the menstrual cycle. CV tissue biopsies, CV secretions, and blood samples were obtained as part of two longitudinal clinical trials of healthy women (CONRAD D11-119 and A12-124 studies). Participants (n = 39) were HIV-seronegative women not using exogenous hormone supplementation, with normal menstrual cycles, who were screened to exclude sexually transmitted and reproductive tract infections. Serum levels of estradiol and progesterone were significantly higher in the LUT versus the FOL phase of the menstrual cycle. Controlling for race, reported contraceptive use/sexual practices, and clinical trial, we found no differences in vaginal tissue immune cell populations and activation status, transcriptomes, inhibition of HIV, herpes simplex virus type 2 and Escherichia coli by the CVL, vaginal pH or Nugent score, or production of p24 antigen after ex vivo infection by HIV-1BaL between CV samples obtained in the FOL phase versus the LUT phase of the menstrual cycle. There were no significant correlations between serum estradiol and progesterone levels and CV endpoints. The hypothesis that the LUT phase of the menstrual cycle represents a more vulnerable stage for mucosal infection with HIV was not supported by data from samples obtained from the lower genital tract (ectocervix and vagina) from these two clinical trials.
Get full access to this article
View all access options for this article.
References
1.
BoilyMC, BaggaleyRF, WangL, et al.: Heterosexual risk of HIV-1 infection per sexual act: Systematic review and meta-analysis of observational studies. Lancet Infect Dis, 2009; 9:118–129.
2.
GrayRH, WawerMJ, BrookmeyerR, et al.: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet, 2001; 357:1149–1153.
3.
WawerMJ, GrayRH, SewankamboNK, et al.: Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis, 2005; 191:1403–1409.
4.
PatelP, BorkowfCB, BrooksJT, LasryA, LanskyA, MerminJ: Estimating per-act HIV transmission risk: A systematic review. AIDS, 2014; 28:1509–1519.
5.
UNAIDS. The Gap Report. 2014. www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport
6.
ReichelderferPS, CoombsRW, WrightDJ, et al.: Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. AIDS, 2000; 14:2101–2107.
7.
PolisCB, PhillipsSJ, CurtisKM, et al.: Hormonal contraceptive methods and risk of HIV acquisition in women: A systematic review of epidemiological evidence. Contraception, 2014; 90:360–390.
8.
GrayRH, LiX, KigoziG, et al.: Increased risk of incident HIV during pregnancy in Rakai, Uganda: A prospective study. Lancet, 2005; 366:1182–1188.
9.
TahaTE, DallabettaGA, HooverDR, et al.: Trends of HIV-1 and sexually transmitted diseases among pregnant and postpartum women in urban Malawi. AIDS, 1998; 12:197–203.
10.
LeroyV, Van de PerreP, LepageP, et al.: Seroincidence of HIV-1 infection in African women of reproductive age: A prospective cohort study in Kigali, Rwanda, 1988–1992. AIDS, 1994; 8:983–986.
11.
WiraCR, FaheyJV: A new strategy to understand how HIV infects women: Identification of a window of vulnerability during the menstrual cycle. AIDS, 2008; 22:1909–1917.
12.
SodoraDL, GettieA, MillerCJ, MarxPA: Vaginal transmission of SIV: Assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Hum Retroviruses, 1998; 14Suppl 1:S119–S123.
13.
VishwanathanSA, GuenthnerPC, LinCY, et al.: High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr, 2011; 57:261–264.
14.
KershEN, HenningT, VishwanathanSA, et al.: SHIV susceptibility changes during the menstrual cycle of pigtail macaques. J Med Primatol, 2014; 43:310–316.
15.
YeamanGR, HowellAL, WeldonS, et al.: Human immunodeficiency virus receptor and coreceptor expression on human uterine epithelial cells: Regulation of expression during the menstrual cycle and implications for human immunodeficiency virus infection. Immunology, 2003; 109:137–146.
16.
YeamanGR, GuyrePM, FangerMW, et al.: Unique CD8+ T cell-rich lymphoid aggregates in human uterine endometrium. J Leukoc Biol, 1997; 61:427–435.
17.
WhiteHD, CrassiKM, GivanAL, et al.: CD3+ CD8+ CTL activity within the human female reproductive tract: Influence of stage of the menstrual cycle and menopause. J Immunol, 1997; 158:3017–3027.
18.
KuttehWH, MoldoveanuZ, MesteckyJ: Mucosal immunity in the female reproductive tract: Correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation. AIDS Res Hum Retroviruses, 1998; 14Suppl 1:S51–S55.
19.
Al-HarthiL, WrightDJ, AndersonD, et al.: The impact of the ovulatory cycle on cytokine production: Evaluation of systemic, cervicovaginal, and salivary compartments. J Interferon Cytokine Res, 2000; 20:719–724.
20.
KellerMJ, MadanRP, TorresNM, et al.: A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One, 2011; 6:e16475.
21.
YeamanGR, AsinS, WeldonS, et al.: Chemokine receptor expression in the human ectocervix: Implications for infection by the human immunodeficiency virus-type I. Immunology, 2004; 113:524–533.
22.
PoppeWA, DrijkoningenM, IdePS, LauwerynsJM, Van AsscheFA: Lymphocytes and dendritic cells in the normal uterine cervix. An immunohistochemical study. Eur J Obstet Gynecol Reprod Biol, 1998; 81:277–282.
23.
PudneyJ, QuayleAJ, AndersonDJ: Immunological microenvironments in the human vagina and cervix: Mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod, 2005; 73:1253–1263.
24.
GivanAL, WhiteHD, SternJE, et al.: Flow cytometric analysis of leukocytes in the human female reproductive tract: Comparison of fallopian tube, uterus, cervix, and vagina. Am J Reprod Immunol, 1997; 38:350–359.
25.
SabaE, OrigoniM, TaccagniG, et al.: Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of the menstrual cycle. Mucosal Immunol, 2013; 6:1081–1090.
26.
Al-HarthiL, KovacsA, CoombsRW, et al.: A menstrual cycle pattern for cytokine levels exists in HIV-positive women: Implication for HIV vaginal and plasma shedding. AIDS, 2001; 15:1535–1543.
27.
KyongoJK, JespersV, GoovaertsO, et al.: Searching for lower female genital tract soluble and cellular biomarkers: Defining levels and predictors in a cohort of healthy Caucasian women. PLoS One, 2012; 7:e43951.
28.
ShustGF, ChoS, KimM, et al.: Female genital tract secretions inhibit herpes simplex virus infection: Correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol, 2010; 63:110–119.
29.
ChappellCA, IsaacsCE, XuW, et al.: The effect of menopause on the innate antiviral activity of cervicovaginal lavage. Am J Obstet Gynecol, 2015; 213:204.e1–e6.
30.
PattersonBK, LandayA, AnderssonJ, et al.: Repertoire of chemokine receptor expression in the female genital tract: Implications for human immunodeficiency virus transmission. Am J Pathol, 1998; 153:481–490.
31.
ACOG Committee on Practice Bulletins–Gynecology: ACOG practice bulletin No. 104: Antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol, 2009; 113:1180–1189.
32.
CulliganPJ, KubikK, MurphyM, BlackwellL, SnyderJ: A randomized trial that compared povidone iodine and chlorhexidine as antiseptics for vaginal hysterectomy. Am J Obstet Gynecol, 2005; 192:422–425.
33.
MarkhamSM, RockJ: Preoperative care. In: TeLinde's Operative Gynecology, Volume 10, 10th edition (RockJ, JonesH, eds.) Lippincott Williams and Wilkins, New York, 2011, pp. 103–163.
34.
NugentRP, KrohnMA, HillierSL: Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol, 1991; 29:297–301.
35.
ThurmanA, KimbleT, NelA, et al.: Safety of cervical and vaginal biopsies in microbicide and contraceptive research. Paper presented at International AIDS Society 2015, Vancouver, BC.
36.
ZalenskayaIA, JosephT, BavarvaJ, et al.: Gene expression profiling of human vaginal cells in vitro discriminates compounds with pro-inflammatory and mucosa-altering properties: Novel biomarkers for preclinical testing of HIV microbicide candidates. PLoS One, 2015; 10:e0128557.
37.
BenjaminiY, HochbergY: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B, 1995; 57:289–300.
38.
Richardson-HarmanN, MauckC, McGowanI, AntonP: Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study. AIDS Res Hum Retroviruses, 2012; 28:1422–1433.
39.
Richardson-HarmanN, Lackman-SmithC, FletcherPS, et al.: Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol, 2009; 47:3530–3539.
40.
DezzuttiCS, UrankerK, BungeKE, Richardson-HarmanN, MacioI, HillierSL: HIV-1 infection of female genital tract tissue for use in prevention studies. J Acquir Immune Defic Syndr, 2013; 63:548–554.
41.
BeagleyKW, GockelCM: Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol, 2003; 38:13–22.
42.
MaZ, LuFX, TortenM, MillerCJ: The number and distribution of immune cells in the cervicovaginal mucosa remain constant throughout the menstrual cycle of rhesus macaques. Clin Immunol, 2001; 100:240–249.
43.
NoyesRW, HertigAT, RockJ: Dating the endometrial biopsy. Am J Obstet Gynecol, 1975; 122:262–263.
44.
PattonDL, ThwinSS, MeierA, HootonTM, StapletonAE, EschenbachDA: Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. Am J Obstet Gynecol, 2000; 183:967–973.
45.
SheffieldJS, WendelGDJr., McIntireDD, NorgardMV: The effect of progesterone levels and pregnancy on HIV-1 coreceptor expression. Reprod Sci, 2009; 16:20–31.
46.
RarickLD, ShangoldMM, AhmedSW: Cervical mucus and serum estradiol as predictors of response to progestin challenge. Fertil Steril, 1990; 54:353–355.
47.
AdamopoulosDA, KapollaN, AbrahamianA, DessyprisA, NicopoulouS, GiannacodemosG: Sex steroids in cervical mucus of spontaneous or induced ovulatory cycles. Steroids, 2000; 65:1–7.
48.
KatzDF, SladeDA, NakajimaST: Analysis of pre-ovulatory changes in cervical mucus hydration and sperm penetrability. Adv Contracept, 1997; 13:143–151.
49.
BullaR, De SetaF, RadilloO, et al.: Mannose-binding lectin is produced by vaginal epithelial cells and its level in the vaginal fluid is influenced by progesterone. Mol Immunol, 2010; 48:281–286.
50.
GargiuloAR, FichorovaRN, PolitchJA, HillJA, AndersonDJ: Detection of implantation-related cytokines in cervicovaginal secretions and peripheral blood of fertile women during ovulatory menstrual cycles. Fertil Steril, 2004; 82Suppl 3:1226–1234.
51.
HwangLY, ScottME, MaY, MoscickiAB: Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium. J Reprod Immunol, 2011; 88:66–71.
52.
ValoreEV, WileyDJ, GanzT: Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infect Immun, 2006; 74:5693–5702.
53.
ThurmanAR, KimbleT, HeroldB, et al.: Bacterial vaginosis and subclinical markers of genital tract inflammation and mucosal immunity. AIDS Res Hum Retroviruses, 2015; 31:1139–1152.
54.
PatelMV, GhoshM, FaheyJV, OchsenbauerC, RossollRM, WiraCR: Innate immunity in the vagina (Part II): Anti-HIV activity and antiviral content of human vaginal secretions. Am J Reprod Immunol, 2014; 72:22–33.
55.
ThurmanAR, DoncelGF: Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: Relationship to HIV acquisition. Am J Reprod Immunol, 2011; 65:89–98.
56.
GajerP, BrotmanRM, BaiG, et al.: Temporal dynamics of the human vaginal microbiota. Sci Transl Med, 2012; 4:132ra152.
57.
YangKH, HendrixC, BumpusN, et al.: A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate. PLoS One, 2014; 9:e106196.
58.
Richardson-HarmanN, HendrixCW, BumpusNN, et al.: Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study. PLoS One, 2014; 9:e111507.
59.
AsinSN, HeimbergAM, EszterhasSK, RollenhagenC, HowellAL: Estradiol and progesterone regulate HIV type 1 replication in peripheral blood cells. AIDS Res Hum Retroviruses, 2008; 24:701–716.
60.
EckhartL, SchmidtM, MildnerM, et al.: Histidase expression in human epidermal keratinocytes: Regulation by differentiation status and all-trans retinoic acid. J Dermatol Sci, 2008; 50:209–215.
61.
LynleyAM, DaleBA: The characterization of human epidermal filaggrin. A histidine-rich, keratin filament-aggregating protein. Biochim Biophys Acta, 1983; 744:28–35.
62.
DinhMH, OkochaEA, KoonsA, VeazeyRS, HopeTJ: Expression of structural proteins in human female and male genital epithelia and implications for sexually transmitted infections. Biol Reprod, 2012; 86:32.
63.
RahmanS, RabbaniR, WachihiC, et al.: Mucosal serpin A1 and A3 levels in HIV highly exposed sero-negative women are affected by the menstrual cycle and hormonal contraceptives but are independent of epidemiological confounders. Am J Reprod Immunol, 2013; 69:64–72.
64.
BirseK, ArnoldKB, NovakRM, et al.: Molecular signatures of immune activation and epithelial barrier remodeling are enhanced during the luteal phase of the menstrual cycle: Implications for HIV susceptibility. J Virol, 2015; 89:8793–8805.
65.
FritzMA, SperoffL: The endocrinology of the menstrual cycle: The interaction of folliculogenesis and neuroendocrine mechanisms. Fertil Steril, 1982; 38:509–529.
66.
SperoffL, Vande WieleRL: Regulation of the human menstrual cycle. Am J Obstet Gynecol, 1971; 109:234–247.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
